Patients with probable laboratory-supported , probable or definite ALS were enrolled by 25 Italian centres and randomly assigned ( 1:1 ) to receive intravenous rhEPO 40,000 IU or placebo fortnightly as add-on treatment to riluzole 100mg daily for 12months .